ANA598: Additional Phase II data

Additional data from an ongoing, double-blind, U.S. Phase II trial in 90 patients showed that 200 and 400 mg ANA598 twice daily plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) achieved 75% and 73% cEVR rates, defined as undetectable HCV RNA levels (<15 IU/mL) at week 12, vs. 63% for placebo plus SOC. At week 12, 41% and 59% of patients receiving 200 and 400 mg ANA598, respectively, developed rash compared to 31% for placebo.

In 18 patients receiving 200 mg oral ANA598 twice daily who achieved cEVR and continued receiving SOC for 12 weeks, 17 had undetectable HCV RNA levels at 24 weeks. Two additional patients in the 200 mg ANA598 group who had detectable HCV RNA levels at 12 weeks achieved undetectable levels at week 24. ...